Reassessing Diabetes and APOE Genotype as Potential Interacting Risk Factors for Alzheimer's Disease.

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY

American Journal of Alzheimers Disease and Other Dementias Pub Date : 2022-01-01 DOI:10.1177/15333175211070912

Kaushik Ravipati, Yunxiao Chen, Joseph R Manns

{"title":"Reassessing Diabetes and APOE Genotype as Potential Interacting Risk Factors for Alzheimer's Disease.","authors":"Kaushik Ravipati, Yunxiao Chen, Joseph R Manns","doi":"10.1177/15333175211070912","DOIUrl":null,"url":null,"abstract":"Objective: To assess whether diabetes alone or in association with Apolipoprotein E (APOE) ε4 genotype increases the risk of Alzheimer's Disease (AD) diagnosis. Methods: A retrospective cohort study of 33,456 participants from the National Alzheimer's Coordinating Center database. Results: Participants with one or two APOE ε4 alleles had 2.71 (CI:2.55-2.88) and 9.37 (CI:8.14-10.78) times higher odds of AD diagnosis, respectively, relative to those with zero ε4 alleles. In contrast, diabetic participants showed 1.07 (CI:0.96-1.18) times higher odds of AD relative to nondiabetics. Diabetes did not exacerbate the odds of AD in APOE ε4 carriers. APOE ε4 carriage was correlated with declines in long-term memory and verbal fluency, which were strongly correlated with conversion to AD. However, diabetes was correlated with working memory decline, which had a relatively weak correlation with AD. Conclusions: Unlike APOE ε4, there was little evidence that diabetes was a risk factor for AD.","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623968/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15333175211070912","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess whether diabetes alone or in association with Apolipoprotein E (APOE) ε4 genotype increases the risk of Alzheimer's Disease (AD) diagnosis. Methods: A retrospective cohort study of 33,456 participants from the National Alzheimer's Coordinating Center database. Results: Participants with one or two APOE ε4 alleles had 2.71 (CI:2.55-2.88) and 9.37 (CI:8.14-10.78) times higher odds of AD diagnosis, respectively, relative to those with zero ε4 alleles. In contrast, diabetic participants showed 1.07 (CI:0.96-1.18) times higher odds of AD relative to nondiabetics. Diabetes did not exacerbate the odds of AD in APOE ε4 carriers. APOE ε4 carriage was correlated with declines in long-term memory and verbal fluency, which were strongly correlated with conversion to AD. However, diabetes was correlated with working memory decline, which had a relatively weak correlation with AD. Conclusions: Unlike APOE ε4, there was little evidence that diabetes was a risk factor for AD.

查看原文本刊更多论文

糖尿病和APOE基因型作为阿尔茨海默病潜在相互作用的危险因素的重新评估。

目的：评估糖尿病单独或与载脂蛋白Eε4基因型相关是否会增加阿尔茨海默病（AD）诊断的风险。方法：对来自国家阿尔茨海默病协调中心数据库的33456名参与者进行回顾性队列研究。结果：与ε4等位基因为零的参与者相比，具有一个或两个APOEε4等基因的参与者诊断AD的几率分别高2.71倍（CI:2.55-2.88）和9.37倍（CI:8.14-17.78）。相比之下，糖尿病参与者患AD的几率是非糖尿病参与者的1.07倍（CI：0.96-1.18）。糖尿病并没有增加APOEε4携带者患AD的几率。APOEε4的携带与长期记忆和语言流利度的下降相关，这与AD的转换密切相关。然而，糖尿病与工作记忆下降相关，工作记忆下降与AD的相关性相对较弱。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Alzheimers Disease and Other Dementias GERIATRICS & GERONTOLOGY-CLINICAL NEUROLOGY

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).